{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+oral+care", "query": { "intervention": "Standard of Care oral care" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1475, "total_pages": 148, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+oral+care&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T10:04:26.432Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02244606", "title": "Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mycoses", "Candidiasis, Invasive", "Candidemia" ], "interventions": [ { "name": "SCY-078", "type": "DRUG" }, { "name": "Fluconazole", "type": "DRUG" }, { "name": "Micafungin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Scynexis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 27, "start_date": "2014-09", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2024-06-25", "last_synced_at": "2026-09-29T10:04:26.432Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02244606" }, { "nct_id": "NCT04154384", "title": "Life Care Specialists (LCS) With a Focus on Patient Pain Management and Prevention of Substance Misuse", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Opioid Use" ], "interventions": [ { "name": "Life Care Specialist (LCS) Intervention", "type": "BEHAVIORAL" }, { "name": "Clinical Coordination with Referrals", "type": "OTHER" }, { "name": "Pilot Study of Pain Management Strategies", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2020-02-21", "completion_date": "2022-12-19", "has_results": true, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-09-29T10:04:26.432Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04154384" }, { "nct_id": "NCT03618355", "title": "Trial of eRapa in Prostate Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "eRapa (encapsulated rapamycin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rapamycin Holdings, Inc. dba Emtora Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 15, "start_date": "2018-08-28", "completion_date": "2019-12-02", "has_results": false, "last_update_posted_date": "2020-03-31", "last_synced_at": "2026-09-29T10:04:26.432Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03618355" }, { "nct_id": "NCT03014687", "title": "Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Antibiotics", "Pituitary Adenoma" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Joseph's Hospital and Medical Center, Phoenix", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 116, "start_date": "2017-07-01", "completion_date": "2019-07", "has_results": false, "last_update_posted_date": "2018-08-15", "last_synced_at": "2026-09-29T10:04:26.432Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03014687" }, { "nct_id": "NCT05103332", "title": "Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Indapamide", "type": "DRUG" }, { "name": "Amlodipine", "type": "DRUG" }, { "name": "Olmesartan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Zilebesiran", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 663, "start_date": "2021-11-05", "completion_date": "2024-09-13", "has_results": true, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-09-29T10:04:26.432Z", "location_count": 74, "location_summary": "Mesa, Arizona • Tempe, Arizona • Bell Gardens, California + 62 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Bell Gardens", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05103332" }, { "nct_id": "NCT06319248", "title": "MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sepsis", "Low Blood Pressure" ], "interventions": [ { "name": "Midodrine", "type": "DRUG" }, { "name": "Standard of Care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 308, "start_date": "2024-05-14", "completion_date": "2029-07-30", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-29T10:04:26.432Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Mankato, Minnesota + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Mankato", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Eau Claire", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06319248" }, { "nct_id": "NCT03587038", "title": "OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "OKN 007", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Photon/Proton IMRT", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 27, "start_date": "2018-09-03", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-09-29T10:04:26.432Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03587038" }, { "nct_id": "NCT05772169", "title": "Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypercortisolism", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Mifepristone 300 MG [Korlym]", "type": "DRUG" }, { "name": "Placebo for mifepristone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1113, "start_date": "2023-03-31", "completion_date": "2024-12-18", "has_results": false, "last_update_posted_date": "2025-01-20", "last_synced_at": "2026-09-29T10:04:26.432Z", "location_count": 36, "location_summary": "Escondido, California • Gardena, California • Huntington Park, California + 29 more", "locations": [ { "city": "Escondido", "state": "California" }, { "city": "Gardena", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05772169" }, { "nct_id": "NCT05026502", "title": "A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Heavy Menstrual Bleeding", "Uterine Fibroids" ], "interventions": [], "intervention_types": [], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "51 Years", "sex": "FEMALE", "summary": "18 Years to 51 Years · Female only" }, "enrollment_count": 23, "start_date": "2021-10-05", "completion_date": "2022-08-30", "has_results": false, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-09-29T10:04:26.432Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05026502" }, { "nct_id": "NCT05405595", "title": "ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced/Metastatic Solid Tumors" ], "interventions": [ { "name": "ADG126", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" }, { "name": "Standard of Care (Trifluridine/Tipiracil-Bevacizumab)", "type": "DRUG" }, { "name": "Standard of care (Fruquintinib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adagene Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2022-06-15", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-09-29T10:04:26.432Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Duarte, California • Irvine, California + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05405595" } ] }